The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer

T. S. Barlow, M. Przybylski, Jeanne Schilder, D. H. Moore, K. Y. Look

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The objective of this study was to evaluate the ability of a preoperative serum CA125 to predict whether optimal debulking (OD) could be achieved for patients with stage III and IV epithelial ovarian cancer (EOC). The records of consecutive patients who underwent primary surgery for EOC at Indiana University Hospital between January 1997 and January 2003 were reviewed. Eligibility criteria included FIGO stage III/IV disease, surgery by gynecologic oncology faculty, preoperative CA125, and an operative note clearly defining volume of residual disease. The Medcalc software statistical package was used to generate a receiver-operating characteristic (ROC) curve. Two hundred and eighty-nine cases of stage III/IV EOC were identified, of which 164 met the eligibility criteria. Serum CA125 ≤400 was associated with OD ≥75% of the time. Conversely, OD was achieved in ≤40% of patients with CA125 ≥4500. The area under the ROC curve for CA125 was .670. The OD rate for those with and without ascites was 49% and 79%, respectively (P < 0.001). In a multivariate analysis using CA125, age, and ascites, the area under the curve was 0.686. We conclude that preoperative serum CA125 did not reliably predict OD in patients with stage III-IV EOC.

Original languageEnglish
Pages (from-to)496-500
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume16
Issue number2
DOIs
StatePublished - Mar 2006

Fingerprint

Ascites
ROC Curve
Neoplasms
Serum
Female Genital Diseases
Gynecologic Surgical Procedures
Residual Volume
Area Under Curve
Software
Multivariate Analysis
Ovarian epithelial cancer

Keywords

  • CA125
  • Ovarian cancer
  • Surgical debulking

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Cancer Research

Cite this

The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. / Barlow, T. S.; Przybylski, M.; Schilder, Jeanne; Moore, D. H.; Look, K. Y.

In: International Journal of Gynecological Cancer, Vol. 16, No. 2, 03.2006, p. 496-500.

Research output: Contribution to journalArticle

@article{b28ce3c739cc4f048a0cfaf709187b69,
title = "The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer",
abstract = "The objective of this study was to evaluate the ability of a preoperative serum CA125 to predict whether optimal debulking (OD) could be achieved for patients with stage III and IV epithelial ovarian cancer (EOC). The records of consecutive patients who underwent primary surgery for EOC at Indiana University Hospital between January 1997 and January 2003 were reviewed. Eligibility criteria included FIGO stage III/IV disease, surgery by gynecologic oncology faculty, preoperative CA125, and an operative note clearly defining volume of residual disease. The Medcalc software statistical package was used to generate a receiver-operating characteristic (ROC) curve. Two hundred and eighty-nine cases of stage III/IV EOC were identified, of which 164 met the eligibility criteria. Serum CA125 ≤400 was associated with OD ≥75{\%} of the time. Conversely, OD was achieved in ≤40{\%} of patients with CA125 ≥4500. The area under the ROC curve for CA125 was .670. The OD rate for those with and without ascites was 49{\%} and 79{\%}, respectively (P < 0.001). In a multivariate analysis using CA125, age, and ascites, the area under the curve was 0.686. We conclude that preoperative serum CA125 did not reliably predict OD in patients with stage III-IV EOC.",
keywords = "CA125, Ovarian cancer, Surgical debulking",
author = "Barlow, {T. S.} and M. Przybylski and Jeanne Schilder and Moore, {D. H.} and Look, {K. Y.}",
year = "2006",
month = "3",
doi = "10.1111/j.1525-1438.2006.00573.x",
language = "English",
volume = "16",
pages = "496--500",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer

AU - Barlow, T. S.

AU - Przybylski, M.

AU - Schilder, Jeanne

AU - Moore, D. H.

AU - Look, K. Y.

PY - 2006/3

Y1 - 2006/3

N2 - The objective of this study was to evaluate the ability of a preoperative serum CA125 to predict whether optimal debulking (OD) could be achieved for patients with stage III and IV epithelial ovarian cancer (EOC). The records of consecutive patients who underwent primary surgery for EOC at Indiana University Hospital between January 1997 and January 2003 were reviewed. Eligibility criteria included FIGO stage III/IV disease, surgery by gynecologic oncology faculty, preoperative CA125, and an operative note clearly defining volume of residual disease. The Medcalc software statistical package was used to generate a receiver-operating characteristic (ROC) curve. Two hundred and eighty-nine cases of stage III/IV EOC were identified, of which 164 met the eligibility criteria. Serum CA125 ≤400 was associated with OD ≥75% of the time. Conversely, OD was achieved in ≤40% of patients with CA125 ≥4500. The area under the ROC curve for CA125 was .670. The OD rate for those with and without ascites was 49% and 79%, respectively (P < 0.001). In a multivariate analysis using CA125, age, and ascites, the area under the curve was 0.686. We conclude that preoperative serum CA125 did not reliably predict OD in patients with stage III-IV EOC.

AB - The objective of this study was to evaluate the ability of a preoperative serum CA125 to predict whether optimal debulking (OD) could be achieved for patients with stage III and IV epithelial ovarian cancer (EOC). The records of consecutive patients who underwent primary surgery for EOC at Indiana University Hospital between January 1997 and January 2003 were reviewed. Eligibility criteria included FIGO stage III/IV disease, surgery by gynecologic oncology faculty, preoperative CA125, and an operative note clearly defining volume of residual disease. The Medcalc software statistical package was used to generate a receiver-operating characteristic (ROC) curve. Two hundred and eighty-nine cases of stage III/IV EOC were identified, of which 164 met the eligibility criteria. Serum CA125 ≤400 was associated with OD ≥75% of the time. Conversely, OD was achieved in ≤40% of patients with CA125 ≥4500. The area under the ROC curve for CA125 was .670. The OD rate for those with and without ascites was 49% and 79%, respectively (P < 0.001). In a multivariate analysis using CA125, age, and ascites, the area under the curve was 0.686. We conclude that preoperative serum CA125 did not reliably predict OD in patients with stage III-IV EOC.

KW - CA125

KW - Ovarian cancer

KW - Surgical debulking

UR - http://www.scopus.com/inward/record.url?scp=33646059529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646059529&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2006.00573.x

DO - 10.1111/j.1525-1438.2006.00573.x

M3 - Article

C2 - 16681717

AN - SCOPUS:33646059529

VL - 16

SP - 496

EP - 500

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 2

ER -